"Highlighting the trial's results, he notes the combination therapy significantly extended median radiographic progression-free survival to 39 months, far surpassing the outcomes with either treatment alone. "
39 months progression free is not bad at all...
These results are specifically in patients with HRR alterations. Most of them were BRCA mutations.
This combination is truly interesting, at least for us with BRCA+. Will bring it up with MO. Thanks for posting.
The posts and communication on the Forum are truly wonderful and inspiring. They help one feel not alone. I am so grateful I found it. Thank you all so much.
FDA Approves Darolutamide Plus Docetaxel for Metastatic Hormone-Sensitive Prostate CancerAbiraterone/prednisone plus olaparib extends time to progression in BRCA/ATM mutated prostate cancer.
Resistant to Zytiga, Xtandi and Chemo? Here is a promising trial.ESMO 2024: darolutamide plus ADT in Patients with mHSPC from ARANOTE Trial
Olaparib & Durvalumab ... ASCO 2017 
